Walter M. Stadler to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Walter M. Stadler has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.636
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
Score: 0.196
-
Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64.
Score: 0.106
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.102
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.096
-
Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5.
Score: 0.054
-
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
Score: 0.032
-
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60.
Score: 0.027
-
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
Score: 0.023